OncoDaily Pulse

Aug 21, 2025, 10:08

Yüksel Ürün: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register here: https://forms.gle/qcQyaGMQfHDhanfD9

Co-Chair of VIRO

Images

Name

Rana McKay

Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Yüksel Ürün

Prof. Yüksel Ürün is a distinguished Professor of Medical Oncology at Ankara University School of Medicine and one of Turkey’s leading experts in genitourinary cancers. With extensive clinical and academic experience, he has been at the forefront of advancing precision oncology and integrating innovative therapies into practice, particularly in renal cell carcinoma (RCC).

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Prof. Ürün will present on “Personalizing Treatment in the Frontline Setting.” His session highlights how treatment decisions in advanced RCC are evolving, with increasing emphasis on tailoring frontline therapy based on patient- and disease-specific factors.

Prof. Ürün will discuss

Individualized treatment strategies in the frontline setting, including how to select between immunotherapy-based combinations and targeted therapies.
Key prognostic and predictive factors that guide clinical decision-making in routine practice.
Balancing efficacy, safety, and quality of life in frontline treatment to optimize outcomes for diverse patient populations.

By focusing on personalization, Prof. Ürün underscores the need to move beyond a “one-size-fits-all” approach. His perspective reflects a broader trend in oncology toward integrating biomarkers, patient characteristics, and real-world considerations into treatment planning.

Through his expertise, Prof. Ürün illustrates how precision oncology in the frontline setting can maximize therapeutic benefit and support more equitable access to modern cancer care across different healthcare systems.